As a representative of tumor immunotherapy, PD‐1/PD‐L1 antibody drugs enhance T cell‐mediated killing of cancer cells and have demonstrated significant efficacy in various advanced malignancies [30, 31]. The gene discussed is CD274; the disease is cancer.